Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.
Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.
Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.
Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.
Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.
For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.
Exelixis announced promising results from the dose-escalation phase of the STELLAR-001 trial, evaluating XL092 as a treatment for advanced solid tumors. The trial showed that XL092 alone and in combination with atezolizumab displayed manageable safety profiles and preliminary clinical activity, especially in heavily pretreated renal cell carcinoma patients. Notably, tumor reduction was observed in 71% of single-agent XL092 patients. The next step involves expanding the trial using the recommended dose of 100 mg across various solid tumors.
Exelixis announced positive results from the COSMIC-313 trial, evaluating cabozantinib in combination with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC). The trial demonstrated a significant reduction in disease progression or death, achieving a hazard ratio of 0.73. Median progression-free survival was not yet reached with the triplet therapy versus 11.3 months for the dual therapy. However, no significant overall survival benefit was noted at interim analysis, prompting continuation for further analysis. The safety profile was consistent with known drug effects.
Exelixis, Inc. (Nasdaq: EXEL) will participate in investor conferences in September. The company is scheduled to present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:05 p.m. ET in New York City, and at the BofA Securities Global Healthcare Conference on September 15, 2022, at 2:10 p.m. BST in London. Webcast access is available on the Exelixis website, with replays provided for 30 days. Exelixis focuses on oncology and has four commercially available products to address difficult-to-treat cancers.
Exelixis reported total revenues of $419.4 million for Q2 2022, marking a 9% increase from $385.2 million in Q2 2021. The cabozantinib franchise generated $347.0 million in revenues, reflecting a 22% year-over-year growth. GAAP diluted EPS was $0.22, while non-GAAP diluted EPS was $0.28. Research and development expenses rose to $199.5 million, up from $148.8 million in the prior year. Exelixis maintains its 2022 revenue guidance of $1.525 billion to $1.625 billion.
Exelixis, Inc. (Nasdaq: EXEL) will release its Q2 2022 financial results on
Exelixis reported that its COSMIC-313 trial met its primary endpoint, showing a significant improvement in progression-free survival (PFS) for patients with advanced kidney cancer when treated with cabozantinib, nivolumab, and ipilimumab. However, the secondary endpoint of overall survival (OS) did not demonstrate a significant benefit, prompting further analysis. Exelixis plans to consult with the FDA regarding a potential regulatory submission. The trial, involving 855 patients, will continue until the next OS analysis.
Exelixis has entered into an exclusive license agreement with Ryvu Therapeutics to develop targeted therapies using Ryvu’s STING agonist technology. Exelixis will pay an upfront fee of
Exelixis (NASDAQ: EXEL) will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, available on-demand starting July 11, 2022. Investors can access the webcast on www.exelixis.com under the News & Events section. Replays will be available for 30 days. Founded in 1994, Exelixis focuses on developing treatments for challenging cancers and has several products on the market, including CABOMETYX® and COMETRIQ®. They are committed to advancing cancer therapies through innovative drug discovery.
Exelixis has initiated the STELLAR-303 trial, a pivotal phase 3 study for XL092, an oral tyrosine kinase inhibitor. This trial assesses the efficacy of XL092 combined with atezolizumab versus regorafenib in approximately 600 patients with metastatic colorectal cancer (CRC) not exhibiting microsatellite instability-high or mismatch repair-deficiency. The primary endpoint is overall survival, with secondary endpoints including progression-free survival. This study addresses a critical treatment gap for patients who have not responded to standard therapies.
Exelixis has announced a strategic partnership with BioInvent to develop novel antibodies aimed at cancer immunotherapy. This collaboration involves an upfront payment of $25 million from Exelixis for rights to select three targets utilizing BioInvent's advanced screening platform. Exelixis plans to leverage its expertise in antibody engineering to advance these therapies and is focused on expanding its biotherapeutics pipeline. The partnership aims to enhance both companies' capabilities in oncology therapeutics.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is Exelixis Inc. known for?
What are the main products of Exelixis?
When was Cometriq first approved?
Who are the key partners of Exelixis?
What type of cancer is Cometriq used to treat?
What is Cabometyx used for?
Where can I find job opportunities at Exelixis?
How has the financial performance of Exelixis been?
What kind of research does Exelixis focus on?
What is the ticker symbol for Exelixis Inc.?
